UCL-TB talks at the 51st (virtual) Union Conference 2020
31 October 2020
The Union’s annual conference is a major date in the diary for TB researchers. This year, the 51st Union World Conference On Lung Health was held online between 20-24 October 2020.
4-month TB treatment success x 2:
The standard treatment for drug-sensitive TB is 6 months, with previous attempts to shorten this leading to relapses of disease. It was announced at the conference that for the first time, a major clinical trial (Study 31, run by CDC) showed that a 4 month regimen is as effective as the standard 6 months.
Not to be outdone, the SHINE trial (see below) has shown that treatment of children with less severe forms of TB can also be reduced from 6 to 4 months.
Work presented by UCL-TB researchers, or on programmes with which UCL-TB is involved, included:
1. The IMPACT study aims to identify and support people who will struggle with sticking to their TB medication in the UK (see published protocol).
IMPACT presentation: Dr Aaron Karat (Queen Margaret University, Edinburgh) presented some of the formative work with qualitative interviews: “A holistic approach: experiences from Europe”.
2. Bedaquiline resistance: After decades without new anti-TB drugs, Bedaquiline is one of a small number of new antibiotics that have been successfully tested and received at least partial approval for use. Understanding how resistance to this drug can occur will be essential for maximising and prolonging its usefulness.
Presentation: Camus Nimmo (UCL Division of Infection & Immunity) talked about work looking at 3500 genome sequences of M. tuberculosis that showed that genetic changes causing bedaquiline resistance were already circulating before the drug was in use (earlier relevant publication; PhD thesis).
3. The SHINE trial aims to shorten TB treatment in children who have less severe forms of TB. At least 1m children develop TB disease every year, with ~250,000 deaths. However they are less able to tolerate drugs and drug formulations used in adults, and their treatment is usually based on trials on adults. It was reported at the meeting that 4 months treatment was as effective as 6 months. SHINE is sponsored by UCL and funded by MRC / DFID / NIHR / Wellcome Joint Global Health Trials and managed by MRC CTU.
Eric Wobudeya (MU JHU Research Collaboration, Kampala, Uganda; ORCID): Main findings of the SHINE trial
Syed Hissar (ICMR-NIRT, Chennai, India): Diagnosing TB lymphadenitis in children
Jessica Workman (Desmond Tutu TB Centre, Stellenbosch University, Cape Town, South Africa): Caregivers’ beliefs in anti-TB medicines
4. The TB-CHAMP trial aims to prevent TB in children who live with someone who has multidrug-resistant (MDR) TB. The trial is sponsored by Stellenbosch University, South Africa, and managed by the MRC Clinical Trials Unit at UCL.
Susan Purchase (Desmond Tutu TB Centre, Stellenbosch University, Cape Town, South Africa): Finding a needle in the haystack: where are children with TB?
5. The STREAM trial aims to shorten treatment of people with MDR TB. Standard treatment can be up to 2 years, and this trial is testing a 9 month regimen. The trial is managed by the MRC Clinical Trials Unit at UCL.
Gareth Hughes (MRC CTU at UCL): Predictive analyses of QT prolongation from ECG monitoring in STREAM stage 1
Ishmael Qawiy (Vital Strategies): Safety first: side effects of old and new drugs
TB at MRC CTU
See here for a list of all TB trials managed by MRC CTU